ADAM KORENKE: Open Payments
NPI 1417995937 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$361 in 16 payments from 10 companies in 2025. Trend: 2023 $150 · 2024 $248 · 2025 $361
Food & beverage: $361
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 6 | $119 |
| ARRAY BIOPHARMA INC | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 1 | $34 |
| Deciphera Pharmaceuticals Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Gilead Sciences, Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
| Merck Sharp & Dohme LLC | 1 | $19 |
Products named: XTANDI, XALKORI, OPDIVO, PADCEV, QINLOCK, LIBTAYO, Trodelvy, INLYTA.
Industry payments across TX — which companies pay providers there.
